Blood-testing company Theranos Inc. recently announced a settlement with the Centers for Medicare & Medicaid Services in which it agreed to stay out of the clinical laboratory business for two years.
Theranos had been in hot water after Medicare inspectors found serious quality control problems at its lab in Newark, Calif., that resulted in the accuracy of tens of thousands of Theranos’s blood testing results being called into question.
Interestingly, under the company’s settlement, the CMS withdrew its earlier revocation of Theranos’s certificates under the Clinical Laboratory Improvement Amendments (CLIA) even though the company agreed to a two-year clinical laboratory participation ban.
Why Maintain Certificates?
Theranos didn’t respond to inquiries about why it wanted to maintain the certificates, but Andrew B. Wachler of Wachler & Associates, P.C., in Royal Oak, Mich., told me the reason may be that revocations remain on a company’s record and have the potential for some collateral consequences.
“Sometimes,” Wachler said, “we will settle a case where our client agrees to do something voluntarily rather than have a mark (i.e., CLIA revocation) on their record.” In addition, Wachler said, a company may be motivated to maintain their certificates because sometimes there is a period of time before a company can reapply after a revocation.
Wachler & Associates is a health-care law firm with experience in all areas of laboratory regulation and compliance.
Bloomberg BNA contacted the CMS for a copy of the settlement, but the records aren’t releasable and would have to be obtained through a Freedom of Information Act request, the CMS said.
Read my full story on Theranos’s settlement with the CMS here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)